Integrated Biopharma Inc (NYSE:INB) Institutional Investor Sentiment Analysis

September 16, 2018 - By Kristen Paramore

Sentiment for Integrated Biopharma Inc (NYSE:INB)

Integrated Biopharma Inc (NYSE:INB) institutional sentiment decreased to 0.47 in 2018 Q2. Its down -1.28, from 1.75 in 2018Q1. The ratio has dropped, as 8 institutional investors increased and started new stock positions, while 17 sold and decreased holdings in Integrated Biopharma Inc. The institutional investors in our partner’s database now have: 2.67 million shares, down from 2.74 million shares in 2018Q1. Also, the number of institutional investors holding Integrated Biopharma Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 11 Increased: 5 New Position: 3.

Cohen & Steers Global Income Builder, Inc. is a closed-end equity mutual fund launched by Cohen & Steers Inc. The company has market cap of $. It is managed by Cohen & Steers Capital Management, Inc. It currently has negative earnings. The fund invests in the public equity markets across the globe.

The stock decreased 0.64% or $0.06 during the last trading session, reaching $9.33. About 64,524 shares traded or 2.37% up from the average. Cohen & Steers Global Income Builder, Inc (NYSE:INB) has declined 2.60% since September 16, 2017 and is downtrending. It has underperformed by 18.22% the S&P500.

Cutter & Co Brokerage Inc. holds 0.22% of its portfolio in Cohen & Steers Global Income Builder, Inc for 58,983 shares. Karpus Management Inc. owns 78,506 shares or 0.03% of their US portfolio. Moreover, Girard Partners Ltd. has 0.02% invested in the company for 11,411 shares. The Illinois-based Guggenheim Capital Llc has invested 0.02% in the stock. Stifel Financial Corp, a Missouri-based fund reported 524,980 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: